Ainos Inc Stock Price, News & Analysis

Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced it is pursuing out-licensing opportunities for five new drug candidates of its low-dose oral interferon-alpha formulation, VELDONA. The candidates have successfully completed Phase 2 trials, with plans to accelerate them to Phase 3 and commercialization. The trials demonstrated VELDONA's effectiveness in treating various conditions, including Sjögren's syndrome and influenza. Ainos has invested nearly $40 million in the development of VELDONA and aims to enhance autoimmunity while minimizing side effects compared to high-dose injections.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced positive results from its preclinical efficacy study of VELDONA®, a low-dose oral interferon formulation, against the Omicron variant of SARS-CoV-2. The study demonstrated significant stabilization in lung inflammation and recovery in hamsters treated with VELDONA®. The results led to an application for Phase 2 clinical trials in patients with mild COVID-19. The treatment showed a better recovery trend, with no observed mixed-cellular inflammation in the VELDONA® group, compared to 50% in the placebo group.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has submitted an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA, aimed at treating mild COVID-19 symptoms. The trial will assess VELDONA's efficacy compared to standard care in a multicenter study in Taiwan. If successful, this could enhance treatments for COVID-19 and other viral infections.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. to test, manufacture, and package its VELDONA product candidates. This agreement aligns with Ainos' plans to submit an IND application for a Phase 2 study to the FDA by year-end. Additionally, Ainos is pursuing clinical trials for VELDONA against COVID-19 and has plans for further studies on thrombocytopenia and Sjögren's syndrome in 2023. This partnership aims to enhance Ainos' manufacturing capabilities and streamline its clinical trial preparations.

Ainos, a diversified medtech company, reported its second quarter financial results for 2022, showing a substantial revenue increase of 213.6% to US$636,627, driven by sales of COVID-19 Antigen Rapid Test Kits. Gross profit reached US$317,664, with a gross margin of 49.9%. However, total operating expenses surged 163.0% to US$2,261,960, impacting net loss, which increased to US$1,954,032. The company highlighted successful product developments, including an Emergency Use Authorization for its COVID-19 test kit in Taiwan, and progress on its VELDONA antiviral formulation.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced the closing of its public offering of 780,000 units at $4.25 per unit, yielding approximately $3.3 million in gross proceeds. Each unit includes one share of common stock and a warrant for one share. The stock underwent a reverse split at a 1-for-15 ratio, effective August 8, 2022. Additionally, the company granted underwriters a 45-day option to purchase an extra 117,000 shares and/or warrants. The offering was conducted under its SEC registration statement, effective as of August 8, 2022.

Ainos, Inc. (OTC PINK: AIMD) announced positive results from a preclinical study of its oral interferon formulation, VELDONA, against COVID-19 in hamsters. The study showed that VELDONA significantly reduced weight loss and viral loads in infected hamsters compared to a control group. Notably, the VELDONA group exhibited a maximum viral load reduction of 720510.66 on day six. Ainos plans to prepare application documents for FDA Phase 2/3 clinical trials, aiming to establish VELDONA's efficacy against COVID-19 and other viral infections.

Ainos, Inc. (OTC PINK:AIMD) has launched the Ainos SARS-CoV-2 Antigen Rapid Self-Test Kit in Taiwan, following Emergency Use Authorization from the Taiwan Food and Drug Administration on June 13, 2022. This at-home test kit enables users to detect the presence of SARS-CoV-2, including the Omicron variant, yielding results in just 15 minutes. The company has previously marketed a professional-use version since June 2021. Ainos aims to meet the rising demand for COVID-19 testing amidst increasing cases, thereby supporting public health measures.

Ainos, Inc. (OTC PINK:AIMD) announced a partnership with InnoPharmax, Inc. to develop a combined therapy for COVID-19. The therapy will utilize Ainos' VELDONA® low-dose interferon platform and InnoPharmax's antiviral drug, GemOral®. The companies will conduct clinical trials in Taiwan and aim for Phase III trials by Q3 2022, targeting emergency use authorization in the U.S. The estimated cost per treatment is approximately USD 500, pending market conditions. This strategic collaboration aims to enhance antiviral treatment options as COVID-19 cases continue to rise.